2026 Hematology Highlights: A Post-ASH Review

The University of Nebraska Medical Center has proudly sponsored this regional conference for almost two decades, highlighting a long-standing commitment to advancing education and collaboration in hematology and oncology.

This year’s conference brings together leading experts to share the latest insights on myeloid diseases, lymphoid and plasma cell disorders, classical hematology, and gene therapy for sickle cell anemia, as presented at the 2025 Annual Meeting of the American Society of Hematology (ASH).

Designed to foster collaboration across disciplines, the conference features a nursing-led roundtable on the point-of-care needs of hospitalized patients with hematologic malignancies, as well as a pharmacy-driven session on infectious prophylaxis for patients receiving bispecific antibody therapy. Participants will also have the opportunity to engage in interactive Q&A sessions, promoting meaningful discussions and enhancing knowledge of these critical topics.

At the conclusion of this activity, the participants should be better able to:

1. Review updates in emerging therapies for frontline and relapsed/refractory leukemia, lymphoma, and multiple myeloma.

2.  Analyze emerging data on new clinical, genetic, and molecular prognostic factors and apply this information to enhance precision approaches for treating hematologic malignancies.

3. Summarize the impact of evidence-based findings from the 2025 ASH meeting on the management of hematologic malignancies and other hematologic diseases.
4. Discuss current evidence and best practice strategies for infectious prophylaxis and monitoring in patients receiving bispecific antibody therapy in academic and community settings.
5. Identify indications, risks, and benefits of gene therapy in sickle cell disease and other classical hematologic diseases.

6. Incorporate multidisciplinary expertise from nurses, pharmacists, advanced practice providers, and physicians in the inpatient care of patients with hematologic malignancies.

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
The University of Nebraska Medical Center designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The University of Nebraska Medical Center designates this activity for 4.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Pharmacists
The University of Nebraska Medical Center designates this activity for 4.0 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

If you need to cancel your registration, please email registrationCCE@unmc.edu no later than Feb. 13, 2026. A $25 processing fee will apply to cancellations received by this date. Please note that if you paid by credit or debit card, the $3 card processing fee is non-refundable. Cancellations made after Feb. 13, as well as registrants who do not attend, are responsible for the full registration fee.

Read the UNMC CCE Disclosure Declaration Policy

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Tania Jain, MBBS
  Advisory Board: Bristol-Myers Squibb Company, Calytrix Bio, Incyte, Kite A GILEAD Company, TScan Therapeutics, Karyopharm Therapeutics, Takeda Pharmaceuticals U.S.A.
  Research Support: CTI Biopharma; Incyte; Kartos Therapeutics, Inc.; Karyopharm Therapeutics; TScan Therapeutics
• Joanna Rhodes, MD, MSCE
  Consultancy: AbbVie Inc.; ADC Therapeutics SA; AstraZeneca; BeOne Medicines (formerly Beigene), Bristol-Myers Squibb Company; Epizyme; Genentech, Inc.; GenMab A/S; Incyte; Loxo Oncology; Janssen Pharmaceuticals, Inc.; Johnson & Johnson and its affiliates; MorphoSys; Pharmacyclics LLC (An AbbVie Company); Pfizer Inc.  
  Honoraria: Aptitude Health; Curio Science, a Vaniam Group company; IDEOlogy Health; MJH Life Sciences
  Research Funding: Acerta Pharma; AbbVie Inc.; BeOne Medicines (formerly Beigene); Epizyme; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Oncternal; Pharmacyclics LLC (An AbbVie Company); VelosBio Inc; Merck & Co., Inc.
• Harsh Shah, DO
  Consultant: ADC Therapeutics SA; Bristol-Myers Squibb Company; Ipsen Pharma; Pfizer Inc.
• Akshay Sharma, MBBS, MSc
  Consultant: BioLineRX Ltd.; Bristol-Myers Squibb Company; Editas Medicine; Gamida Cell; Medexus Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated; RGenta Therapeutics; Pfizer Inc.
• Aditi Shastri, MBBS
  Advisory Board: Caris Life Sciences; Geron; Kymera Therapeutics, Inc.; RYVU
  Consultant: Servier Pharmaceuticals
  Research Funding: Kymera Therapeutics, Inc.; RYVU

• Christopher Strouse, MD
  Advisory Board: Legend Biotech; Pfizer Inc.
  Research Funding: Bristol-Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; F. Hoffmann-La Roche Ltd 

The following have nothing to disclose:

• Alaina G. Chick, BSN, RN, BMTCN

• Lindsay M. Draft, BSN, RN, OCN

• Haley Rust, PharmD, BCOP

• Caner Saygin, MD

• Lindsay N. Smith, BSN, RN, BMTCN

PLANNING COMMITTEE

The following have disclosed relevant financial relationships:

• Christopher R. D’Angelo, MD
  Advisor: ADC Therapeutics SA; BeOne Medicines (formerly Beigene); Bristol-Myers Squibb Company; Curis Inc.; Pfizer Inc.
  Consultant: AbbVie Inc.
  Research Funding: AbbVie Inc., Bristol-Myers Squibb Company, Genmab A/S
• Krishna Gundabolu, MBBS, MS
  Advisory Board: Incyte, Swedish Orphan Biovitrum AB (SOBI)
• Jared Matya, PharmD, BCOP
  Consultant: AstraZeneca, Bristol-Myers Squibb Company, Genmab A/S, Sanofi, SERB Pharmaceuticals
  Speaker’s Bureau: SERB Pharmaceuticals

The following planning committee members have nothing to disclose:

• Valeta Creason-Wahl, CAPM, MMP
• Tori Greenlee
• Julie Huglin
• Heidi Keeler, PhD, MSN/MBA, RN
• Renee Paulin, DNP, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP